等待开盘 11-18 09:30:00 美东时间
-0.090
-8.88%
11月18日,Cellectar Biosciences Inc.(CLRB)收跌8.88%,报0.92美元,成交额7.37万美元,市值923.91万美元。 行...
今天 09:00
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• # Cellectar Biosciences(CLRB)2026财年第三季度业绩回顾摘要 ## 1. 财务业绩:**现金及现金等价物:** - 截至2026年9月30日为2,460万美元,较2025年12月31日的1,320万美元有所增加。 - 该增长主要反映了2026年5月完成的超额认购融资带来的约3,170万美元净收益(该融资包含3,500万美元的预付款及1.05亿美元的里程碑式资本)。 - 公司现金可支撑运营至2027年第二季度。 **研发费用(R&D):** - 2026年第三季度为540万美元,上年同期(2025年第三季度)为250万美元
11-11 12:52
11月11日,Cellectar Biosciences Inc.(CLRB)收跌4.69%,报1.22美元,成交额7.98万美元,市值1153.19万美元。...
11-11 08:53
Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.56) by 17.86 percent. This is a 67.38 percent increase over losses of $(1.41) per share from the same period last year.
11-10 20:01
11月7日,Cellectar Biosciences Inc.(CLRB)收涨8.7%,报1.25美元,成交额9.32万美元,市值1181.52万美元。 行情...
11-07 08:51
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters highlighting compelling data and clinical progress for its lead radiopharmaceutical candidate, iopofosine I 131...
11-04 22:08
Cellectar Biosciences announced that three posters highlighting data for its lead radiopharmaceutical candidate, iopofosine I 131 in Waldenström macroglobulinemia (WM), will be presented at the ASH Annual Meeting. The posters will include updated 12-month follow-up data from the Phase 2b CLOVER WaM trial, showing durable responses in heavily pretreated patients and suggesting greater benefit when used earlier in treatment. The company will also p...
11-04 14:00
10月31日,Cellectar Biosciences Inc.(CLRB)收跌1.23%,报1.21美元,成交额6.6万美元,市值1138.98万美元。 行...
10-31 07:54
10月30日,Cellectar Biosciences Inc.(CLRB)收跌1.61%,报1.22美元,成交额13.69万美元,市值1153.16万美元...
10-30 07:56
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a Range of B-cell Malignancies FLORHAM PARK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) --...
10-27 19:16